title: Mitochondrial dysfunction in epilepsy.
abstract: Epilepsy is the most common neurologic disorder worldwide and is characterized by recurrent unprovoked seizures. The mitochondrial (mt) respiratory chain is the final common pathway for cellular energy production through the process of oxidative phosphorylation. As neurons are terminally differentiated cells that lack significant regenerative capacity and have a high energy demand, they are more vulnerable to mt dysfunction. Therefore, epileptic seizures have been well described in several diseases such as mt encephalomyopathy, lactic acidosis, and stroke-like episodes and myoclonic epilepsy and ragged red fibers, which are caused by gene mutations in mtDNA, among others. Mutations in nuclear DNA regulating mt function are also being described (eg, POLG gene mutation). The role of mitochondria (mt) in acquired epilepsies, which account for about 60% of all epilepsies, is equally important but less well understood. Oxidative stress is one of the possible mechanisms in the pathogenesis of epilepsy resulting from mt dysfunction gradually disrupting the intracellular Ca(2+) homeostasis, which modulates neuronal excitability and synaptic transmission, making neurons more vulnerable to additional stress, and leading to energy failure and neuronal loss in epilepsy. Antiepileptic drugs (AEDs) also affect mt function in several ways. There must be caution when treating epilepsy in patients with known mt disorders as some AEDs are toxic to the mt. This review summarizes our current knowledge of the effect of mt disorders on epilepsy, of epileptic seizures on mt, and of AEDs on mt function and the implications of all these interactions for the management of epilepsy in patients with or without mt disease.
authors: Section of Neurology, Departments of Pediatrics and Neurology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA. Electronic address: divya.khurana@drexelmed.edu.
authors: Divya S
authors: DS
authors: Khurana
authors: Section of Neurology, Departments of Pediatrics and Neurology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA.
authors: Ignacio
authors: I
authors: Valencia
authors: Section of Neurology, Departments of Pediatrics and Neurology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA.
authors: Michael J
authors: MJ
authors: Goldenthal
authors: Section of Neurology, Departments of Pediatrics and Neurology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA.
authors: Agustín
authors: A
authors: Legido
mesh_terms: D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D004272:DNA, Mitochondrial / Q000235:genetics; D004827:Epilepsy / Q000150:complications / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D028361:Mitochondrial Diseases / Q000150:complications / Q000235:genetics* / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D009154:Mutation
chemical_list: D000927:Anticonvulsants; D004272:DNA, Mitochondrial